Publications by authors named "Domenico Laviola"

Introduction: Gliflozins are recommended as first-line treatment in patients with heart failure and/or cardiovascular comorbidities and are demonstrated to reduce atrial fibrillation (AF) occurrence. However, it is not well known which gliflozin yields the larger cardioprotection in terms of AF occurrence reduction. Hence, we aimed to compare data regarding AF recurrence associated with different gliflozins.

View Article and Find Full Text PDF

Atrial fibrillation, representing the most prevalent sustained cardiac arrhythmia, significantly impacts stroke risk and cardiovascular mortality. Historically managed with antiarrhythmic drugs with limited efficacy, and more recently, catheter ablation, the interventional approach field is still evolving with technological advances. This review highlights pulsed field ablation (PFA), a revolutionary technique gaining prominence in interventional electrophysiology because of its efficacy and safety.

View Article and Find Full Text PDF

Pediatric cardiomyopathies (CMs) and electrical diseases constitute a heterogeneous spectrum of disorders distinguished by structural and electrical abnormalities in the heart muscle, attributed to a genetic variant. They rank among the main causes of morbidity and mortality in the pediatric population, with an annual incidence of 1.1-1.

View Article and Find Full Text PDF

Parenteral prostanoids are being recommended in pulmonary arterial hypertension (PAH) treatment, but the prognostic relevance of delayed treatment initiation is still debated. This study assessed the impact of the timing of prostacyclin treatment initiation on reducing PVR and achieving a low-risk profile in PAH patients. The study enrolled 151 patients who started on parenteral prostanoids with different treatment strategies.

View Article and Find Full Text PDF
Article Synopsis
  • This review highlights recent advancements in the medical management of pulmonary arterial hypertension (PAH) and emphasizes its importance for patient quality of life and prognosis.
  • Recent studies indicate that aggressive treatment strategies can significantly reduce heart stress and improve survival rates, especially in high-risk PAH patients.
  • Notable trials like PULSAR and STELLAR have shown positive outcomes with new treatments like sotatercept, and ongoing research promises further innovations in targeting PAH-related biological pathways.
View Article and Find Full Text PDF